AmerisourceBergen, a global healthcare services company headquartered in Greater Philadelphia, announced it has formally established a cell and gene therapy service line as part of its commitment to support cell and gene therapy innovators. This new service line will be led by Lung-I Cheng, Ph.D., who recently joined AmerisourceBergen as Vice President of Cell and Gene Therapy. 

Cheng will work to evolve and enhance the end-to-end support AmerisourceBergen provides cell and gene therapy innovators throughout the commercialization journey. As part of that effort, Cheng noted AmerisourceBergen is laser-focused on enhancing its technology and data integration and establishing a forward-looking model so the company can work with its customers in lockstep.

“I’ll work with teams across the company to build upon our existing cell and gene therapy capabilities and develop new solutions that help innovators bring these products to market and ensure they reach the patients who need them,” Cheng said. “Our goal is to build a robust cell and gene therapy solution that can be tailored to the specific needs of biopharma companies, providers, and the patients they serve.” 

Cheng brings a decade of experience in biopharma to his new role. Most recently, he served as the head of Global Value & Access for Cell Therapies, Pipeline, and Business Development at Takeda.

“AmerisourceBergen is one of the founding supporters of Greater Philadelphia’s Cell & Gene Therapy Initiative,” said Claire Marrazzo Greenwood, Executive Director and Senior Vice President of Economic Competitiveness for the Chamber of Commerce for Greater Philadelphia. “We want to congratulate our partner on the establishment of this new service line and join in recognizing AmerisourceBergen for all it does to advance Greater Philadelphia’s role as a leader in cell and gene therapy.”

Through its network of businesses, AmerisourceBergen offers a wide range of commercialization solutions to support cell and gene therapy innovators in areas that include clinical trial and commercial logistics, and market access and reimbursement support. Learn more here.